Amid reports of a major breakthrough of Russia becoming the first nation to complete the first human’s clinical trials of a coronavirus vaccine, the Russian Health Minister Mikhail Murashko has now said that they will make the coronavirus vaccine available to the general public before it clears the third and last phase of clinical trials.
Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow, Russia has reportedly developed a Coronavirus vaccine candidate which will be now tested in its third and final phase of clinical trials but before that Russia has signaled that they may make it available in the market for the general public.
According to Murashko, there will be additional clinical research on the approved vaccine’s safety and efficacy.
To be sure, the vaccine developed by Russia is on the WHO-monitored list for coronavirus vaccine development along with 22 other candidate vaccines.
The details of coronavirus vaccine developed by Russia
In June, Russia permitted two formulations for clinical trials of COVID-19 vaccine applicants. The vaccine was developed by Gamaleya National Research Center for Epidemiology and Microbiology.
At Burdenko Military Hospital the intramuscular solution of the vaccine was experienced whereas for the preparation of an intramuscular solution the vaccine is evaluated at Sechenov University.
The trials were conducted on two different groups, one group containing 18 participants while the second group involved 20 participants.
After the first human clinical trials of the coronavirus vaccine, Sechenov University in Russia claimed that it had concluded its study saying “The research has been completed and it proved that the vaccine is safe”.
Currently, Russia is at number four in coronavirus cases with 771,546 COVID-19 confirmed cases. The total number of recoveries is 550,344 and 12,342 faced deaths due to coronavirus.
Overall corona cases around the world crossed 14.5 million with 605,833 deaths and recovered patients are 8,649,605.
Image source link